Shinya Uchida

Shinya Uchida

Auto-generated profile, based on publicly available information

Shinya Uchida

Departments of Pharmacy Practice and Science, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
STShimako Tanaka
Shimako Tanaka
SUShinya Uchida
Shinya Uchida
NINaoki Inui
Naoki Inui
KTKazuhiko Takeuchi
Kazuhiko Takeuchi
HWHiroshi Watanabe
Hiroshi Watanabe
NNNoriyuki Namiki
Noriyuki Namiki
A “cocktail” approach, which involves simultaneous administration of multiple CYP-specific probes, concurrently detects the activity of multiple CYP enzymes. We developed and validated a rapid and selective LC-MS/MS method for determining the plasma concentrations of 5 CYP probe drugs and metabolites (caffeine/paraxanthine, CYP1A2 substrate; losartan/losartan carboxylic acid (E3174), CYP2C9 substrate; omeprazole/5-hydroxyomeprazole, CYP2C19 substrate; dextromethorphan/dextrorphan, CYP2D6 substrate; and midazolam/1′-hydroxymidazolam, CYP3A4 substrate) by single-step extraction, followed by a single LC-MS/MS run. An Ostro™ 96-well plate was used for extraction of CYP substrates and metabolites from human plasma and urine. Following optimization of the chromatographic conditions, all the peaks were well separated, and retention times ranged between 4.4 and 11.7 min. The total run time for a single injection was within 13 min. The accuracy and precision values suggested that the assay had high accuracy and reliability in plasma and urine samples. No significant matrix interference was observed. To demonstrate the efficacy of this method, plasma and urine concentrations of 5 CYP probe substrates and their metabolites were determined after simultaneous oral administration of 5 drugs to 4 healthy volunteers. All the substrates and metabolites were detected over an 8 h period, and the plasma concentrations of each substrate at 8 h after administration were above the lower limit of quantification. Urine concentrations of drugs and their metabolic ratio were evaluated after the administration. In conclusion, the advantage of our cocktail approach is that it enables in vivo assessment of the activity of various drug-metabolizing enzymes in a single assay.

1 February 2019 in Chemical and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
HTHidehito Takano
Hidehito Takano
SUShinya Uchida
Shinya Uchida
YKYasuharu Kashiwagura
Yasuharu Kashiwagura
STShimako Tanaka
Shimako Tanaka
AHAkio Hakamata
Akio Hakamata
NNNoriyuki Namiki
Noriyuki Namiki
Orally disintegrating tablets (ODTs), which are administered without water, are beneficial for elderly patients and patients with dysphagia. Masking the unpleasant taste of a drug is an important factor associated with adherence of patients consuming ODTs. We prepared cocoa powder-containing ODTs of bitter-tasting rebamipide (rebamipide chocolet) and evaluated their clinical palatability. We prepared rebamipide ODTs by adding a sweetener and 0, 2.5, 5, and 10% cocoa powder (Ch0-ODTs, Ch2.5-ODTs, Ch5-ODTs, and Ch10-ODTs, respectively). Rebamipide ODTs without cocoa powder and sweetener were used as controls (Cont-ODTs). We performed a gustatory sensation test in 30 healthy adult volunteers. We used the 100-mm visual analog scale (VAS) to evaluate bitterness, sweetness, scent, and overall palatability of the ODTs. The acceptability of each ODT was evaluated on a 5-point scale. Compared to Cont-ODTs, Ch0-ODTs showed no significant improvement in the VAS score for bitterness, scent, and overall palatability during disintegration. However, compared to Cont-ODTs, Ch2.5-ODTs, Ch5-ODTs, and Ch10-ODTs showed an improvement in all items evaluated using the VAS. In particular, Ch2.5-ODTs showed a significant improvement compared to the Cont-ODTs in the VAS score of all items. Evaluation on a 5-point scale indicated that Ch2.5-ODTs and Ch10-ODTs had the highest acceptability. We prepared rebamipide chocolet with excellent palatability properties, which could not be achieved using a sweetener alone, by using the combination of a sweetener and cocoa powder as a new agent for masking bitterness. Our results indicate that cocoa powder may be used as a taste-masking agent in ODTs.

2 November 2017 in Xenobiotica
Verified
Journal Article
Closed access
OYOsamu Yasumuro
Osamu Yasumuro
SUShinya Uchida
Shinya Uchida
YKYasuharu Kashiwagura
Yasuharu Kashiwagura
ASAyae Suzuki
Ayae Suzuki
STShimako Tanaka
Shimako Tanaka
NNNoriyuki Namiki
Noriyuki Namiki
1. Although drug interactions between epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and gastric acid-suppressing medications (AS) are considered clinically significant, there is limited data regarding the influence of various gastric pH conditions on the pharmacokinetics of EGFR-TKIs. We aimed to clarify the changes in the pharmacokinetics of the EGFR-TKIs, gefitinib, erlotinib and osimertinib, due to the changes in gastric pH after administration of omeprazole or vonoprazan. 2. Omeprazole (10−100 mg/kg, p.o.) and vonoprazan (1−5 mg/kg, p.o.) led to a significant and dose-dependent increase in gastric pH. 3. AUC0–3 of gefitinib and erlotinib (5 mg/kg, p.o.) started to decrease at gastric pH 3.3 and 5.6, respectively, reached a plateau at pH > 6, and then significantly decreased up to 47 and 59% of control levels, respectively. AUC0–3 of osimertinib (5 mg/kg, p.o.) was not significantly changed by omeprazole and vonoprazan. 4. Although there are some issues regarding the extrapolation of the results of our rat study to humans, careful monitoring of patients treated with gefitinib and erlotinib is needed in cases in which the gastric pH increases from 3 to 5 and especially when the gastric pH is >5 in patients who are co-administered both the EGFR-TKIs and AS.

1 December 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YKYuuki Kasashima
Yuuki Kasashima
SUShinya Uchida
Shinya Uchida
KYKeiichi Yoshihara
Keiichi Yoshihara
TYTakehiko Yasuji
Takehiko Yasuji
KSKazuhiro Sako
Kazuhiro Sako
NNNoriyuki Namiki
Noriyuki Namiki

2 January 2014 in Biopharmaceutics & Drug Disposition
Verified
Journal Article
Closed access
PDF file
SUShinya Uchida
Shinya Uchida
STShimako Tanaka
Shimako Tanaka
NNNoriyuki Namiki
Noriyuki Namiki

1 June 2020
Verified
Journal Article
Closed access
STS. Tanaka
S. Tanaka
SUS. Uchida
S. Uchida
AHA. Hakamata
A. Hakamata
SMS. Miyakawa
S. Miyakawa
KOK. Odagiri
K. Odagiri
NNN. Namiki
N. Namiki